Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDialysis/Renal ReplacementSierra Health and Life Home Hemodialysis Coverage …
    Ask Trek AI about this page
    Currentsierra health and lifePolicy 2026T0476Y

    Home Hemodialysis (HHD) Coverage Criteria

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026T0476Y alerts

    Get alerted when Policy 2026T0476Y changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage and medical necessity criteria for home hemodialysis (with and without skilled care) as an alternative to facility-based hemodialysis for individuals with end-stage renal disease covered by the payer's commercial and individual exchange plans.

    Policy Summary
    Payersierra health and life
    PolicyHome Hemodialysis (HHD) Coverage Criteria
    Policy CodePolicy 2026T0476Y
    Change TypeTemplate update (non-material)
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document stability on dialysis, completed training (CPT 90989 or 90993 as applicable), and well-functioning vascular access.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Template Update noted in policy history.

    3x/weektypical facility hemodialysis frequency referenced
    90963-90970CPT/HCPCS codes listed
    10+ECRI review studies (NxStage)
    58,984subjects in pooled analysis
    3.76 vs 6.27mortality rate HHD vs in-center

    Coverage and Medical Necessity Criteria for Home Hemodialysis

    HHD without skilled care

    Covered when ALL of the following are met

    HHD without skilled care criteria: 1) Individual is stable on dialysis with no evidence of skilled care interventions being necessary during treatments; 2) Individual undergoing hemodialysis or non-professional caregiver has the ability to perform and maintain home hemodialysis and has received comprehensive training regarding proper protocol; 3) Absence of complications and significant concomitant disease that would cause home hemodialysis to be unsafe or unsuitable; 4) Individual has well-functioning vascular access

    From coverage rationale (chunks 3,7)

    HHD with skilled care (staff-assisted)

    Covered when ALL of the following are met

    HHD with skilled care criteria: 1) Individual is stable on dialysis and not at increased risk as a result of having the procedure performed outside a dialysis center venue; 2) Individual undergoing hemodialysis or non-professional caregiver is not capable of performing home hemodialysis; 3) Individual has medical contraindications to leaving home for hemodialysis; 4) Individual has well-functioning vascular access; 5) Staff-assisted HHD protocols generally match those provided in the hemodialysis center (i.e., 3 times per week, 3-4-hour treatments); exact therapy determined by the attending nephrologist

    From coverage rationale (chunk 3)

    Clinical evidence summary

    evidence_summary: Multiple randomized trials, cohort studies, and systematic reviews report that more frequent or extended-duration home hemodialysis in selected populations is associated with improvements in blood pressure control, left ventricular mass, some quality-of-life measures, dialysis-related biochemical control, and in some observational cohorts lower mortality; however, the overall strength of evidence is low to very low for many outcomes and findings are limited by small trials, heterogeneity, and potential selection bias in observational studies.

    See Ok et al. (2023), Weinhandl/Weinhandl et al., Miller et al., and FHN trials (chunks 18,21,27,30)

    Evidence and Guideline-based considerations

    Guidance and evidence highlights relevant to coverage decisions

    Survival and modality: Cohort and systematic review evidence indicate that home hemodialysis with permanent vascular access is associated with lower early mortality compared with facility HD with permanent access; PD and facility HD with catheter are associated with higher risk (Kasza et al.).

    Supported by Kasza et al. (chunk 36)

    Pregnancy outcomes: In pregnant patients on dialysis, more hours of HD per week are associated with reduced adverse outcomes though preterm delivery remains common; dialysis schedule is a primary determinant of outcomes (Piccoli et al.).

    Supported by Piccoli et al. (chunks 36-37)

    Home dialysis comparative effectiveness: Systematic review evidence (Ishani et al.) suggests low-strength evidence that home-based dialysis may provide similar health outcomes and similar or lower costs for many patients compared to in-center HD; selection factors and barriers require further research.

    Supported by Ishani et al. and related reviews (chunk 37)

    Individuals with complications or significant concomitant disease that would make home hemodialysis unsafe or unsuitable are excluded from coverage under standard HHD criteria. This includes patients who are not clinically stable on dialysis, those with active conditions that require skilled nursing or procedural interventions during treatments, and those lacking a well-functioning vascular access. Coverage requires demonstration that the patient and any non‑professional caregiver have the ability to perform and maintain HHD and have completed comprehensive training; absence of these conditions supports exclusion from HHD coverage.

    Findings from the FHN Nocturnal Trial warrant caution: the trial did not demonstrate definitive benefit of nocturnal six‑times‑weekly home dialysis for the primary outcomes and secondary analyses suggested a trend toward increased vascular access events in the nocturnal arm. Extended follow‑up also identified an increased mortality signal in the nocturnal group, indicating that the survival implications of intensive nocturnal regimens remain uncertain and require further investigation before broadly endorsing nocturnal HHD.

    The NKF/KDOQI work group reviewed the evidence and concluded that, owing to inconclusive efficacy data and potential for increased harm, no firm recommendation could be made in favor of routine home long frequent hemodialysis. The guideline statements emphasize that conventional in‑center HD remains the most common treatment and that evidence supporting home short frequent or long frequent HHD is insufficient to support broad endorsement.

    Home hemodialysis is considered not medically necessary when the patient is clinically unstable on dialysis, requires skilled interventions during treatments, or lacks the training, ability, or an available caregiver to perform HHD safely. Lack of a well‑functioning vascular access is also a contraindication to HHD under the policy. In such cases, facility‑based dialysis is the appropriate setting.

    The body of evidence for more frequent or longer-duration hemodialysis contains many limitations: overall quality is rated as low to very low for several critical outcomes, trial populations were often younger and healthier than the general dialysis population, and many studies were underpowered for mortality. Consequently, the magnitude and generalizability of benefits for frequent or extended HHD remain uncertain and require individualized justification.

    Potential harms identified in randomized trials and systematic reviews include inconsistent improvement in key clinical outcomes and an increased frequency of vascular access procedures with more frequent or longer HD regimens. Some trials also failed to show mortality or left ventricular mass benefits, and the balance of modest physiologic improvements against procedural risks and uncertain effects on survival should be considered when selecting HHD schedules.

    Applicable Procedure, Service, and Measurement Codes

    Applicable procedure and service codesmixed
    90963End-stage renal disease (ESRD) related services for home dialysis per full month, for patients younger than 2 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
    90964End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 2-11 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
    90965End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 12-19 years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents.
    90966End-stage renal disease (ESRD) related services for home dialysis per full month, for patients 20 years of age and older.
    90967End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients younger than 2 years of age.
    90968End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 2-11 years of age.
    90969End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 12-19 years of age.
    90970End-stage renal disease (ESRD) related services for dialysis less than a full month of service, per day; for patients 20 years of age and older.
    90989Dialysis training, patient, including helper where applicable, any mode, completed course.
    90993Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session.
    1–10 of 12
    1/2
    Study/device identifiersmixed
    No codes listed
    spKt/V target and related dosing guidance
    Target spKt/V per thrice-weekly HD sessionspKt/V target 1.4 per hemodialysis session (minimum delivered 1.2)
    Adjustments for residual kidney functionDialysis dose may be reduced if significant residual native kidney function exists, with periodic measurement of Kru to avoid inadequate dialysis.
    When to increase sessions or durationConsider additional sessions or longer treatment times for large interdialytic weight gains, high ultrafiltration rates, poorly controlled BP, difficulty achieving dry weight, or poor metabolic control (hyperphosphatemia, metabolic acidosis, hyperkalemia).

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required for HHD services

    Prior authorization is required for home hemodialysis services billed under the listed codes and coverage is contingent on meeting the policy's medical necessity criteria (stability on dialysis, completion of training, well‑functioning vascular access, and absence of contraindicating comorbidities). Submit PA requests using the applicable procedure/service codes: 90963–90970, 90989, 90993, 99512, and S9335.

    • Coverage contingent on meeting medical necessity criteria: stable on dialysis; training completed; absence of unsafe comorbidities; well‑functioning vascular access.
    • Use the listed CPT/HCPCS codes when requesting prior authorization.
    Prior Authorization

    Justify HHD modality and device use in PA

    When requesting prior authorization that involves a specific HHD device or modality (e.g., Tablo system), include clinical justification and device‑specific training/support plans; clinical trial and device study reports cited in the evidence assessment are limited by small samples and short durations and should not substitute for case‑specific justification.

    Background on Hemodialysis and Home Hemodialysis

    Hemodialysis (HD) is a form of renal replacement therapy that removes solutes and fluid by diffusion and ultrafiltration across an extracorporeal circuit. Conventional in‑center HD is typically provided three times per week for about three to five hours per session. Home hemodialysis (HHD) enables patients to receive HD at home using user‑friendly machines and may permit more frequent or longer sessions tailored to patient needs. Appropriate candidates for HHD are clinically stable on dialysis, have a well‑functioning vascular access (for example, an arteriovenous fistula is preferred), and possess the training and home support necessary to perform and maintain therapy safely.

    Definitions and Key Terms

    Vascular access — examples and purpose
    Definition / examplesVascular access options include arteriovenous fistula (AVF), arteriovenous graft (AVG), and indwelling dialysis catheter.
    Preferred accessArteriovenous fistulas (AVFs) are the 'gold standard' due to far fewer complications compared with grafts or catheters.
    PurposeProvides adequate blood flow to the extracorporeal circuit to accomplish ultrafiltration and diffusion during hemodialysis.
    Patient considerationsIndividuals performing HHD should be encouraged to learn AVF/AVG needle access despite apprehension; catheters avoid skin puncture but increase infection risk.
    More frequent HD — definition and context
    DefinitionMore frequent hemodialysis is defined as four or more treatments per week.
    Policy Summary
    Payersierra health and life
    PolicyHome Hemodialysis (HHD) Coverage Criteria
    Policy CodePolicy 2026T0476Y
    Change TypeTemplate update (non-material)
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and document stability on dialysis, completed training (CPT 90989 or 90993 as applicable), and well-functioning vascular access.
    SourceLink
    On This Page
    Coverage and Medical Necessity Criteria for Home HemodialysisApplicable Procedure, Service, and Measurement CodesProvider Requirements, Prior Authorization, and DocumentationBackground on Hemodialysis and Home HemodialysisDefinitions and Key Terms
    Frequency and duration effects: RCTs and systematic reviews show that more frequent (>3/week) or extended-length HD did not consistently improve all clinical outcomes and were associated with increased vascular access procedures; evidence quality is low and mortality effects are uncertain.

    Supported by Slinin et al. and FHN trial reports (chunks 38,30)

    Guideline recommendations (NKF/KDOQI): Offer short frequent in-center HD as an alternative to conventional thrice-weekly HD; consider home long hemodialysis (6–8 hours, 3–6 nights/week) for patients who prefer it; recommend spKt/V target 1.4 per thrice-weekly session (minimum 1.2); individualize dose for residual kidney function and for issues such as large interdialytic weight gains or poorly controlled blood pressure.

    Supported by NKF/KDOQI guideline statements (chunks 40,41)

    AHA statement: The AHA notes home dialysis may improve cardiovascular outcomes compared with thrice-weekly in-center HD but calls for more generalizable outcome trials and expanded training/workforce to increase access to home therapies.

    Supported by AHA statement (chunk 39)

    Shared decision-making and choice: NICE and other guidance recommend offering patients a choice of dialysis modalities, with decisions informed by clinical considerations and patient preferences.

    Supported by NICE guidance (chunk 42)

    • Include indication, device model or system, and a description of training and support for patient/caregiver.
    • Reference relevant trial/device study outcomes only as supporting evidence, not sole justification.
    Note

    PA depends on member's benefit plan

    Prior authorization requirements and the application of this policy depend on the member's specific benefit plan; verify and follow the member‑specific benefit document (and applicable federal/state mandates) before requesting authorization. This policy may be applied to Medicare Advantage in the absence of NCD/LCD guidance, per MAO rules.

    • Check the member‑specific benefit plan document; in the event of conflict, the member plan governs.
    • For Medicare Advantage members, confirm whether NCD/LCD exist; absent such guidance, MAO-level determinations may apply.
    Step Therapy

    No step therapy required by policy

    No formal step therapy sequence is specified in this policy; modality selection is determined by the attending nephrologist based on patient capability, contraindications, and individualized clinical judgment.

    • Document clinical rationale for choosing HHD versus in‑center modalities when relevant to coverage decisions.
    Step Therapy

    Consider home dialysis as step from in‑center care

    Consider home dialysis as a clinically appropriate step from in‑center care when supported by multidisciplinary care and documented clinical benefit; systematic reviews associated home dialysis and multidisciplinary interventions with lower mortality and hospitalizations in observational studies.

    • When transitioning from in‑center to home dialysis, document multidisciplinary supports (training, nursing/care coordination) and rationale tied to patient outcomes.
    Step Therapy

    No explicit step therapy rules in policy

    This document does not establish explicit step therapy rules or mandatory prior in‑center trial requirements for HHD; absence of such rules means clinical selection remains individualized.

    • If a plan sponsor imposes step requirements, follow the member‑specific benefit plan terms.
    Documentation Required

    Required clinical documentation for PA

    Provide clinical documentation that supports the member is stable on dialysis, has completed or is enrolled in a dialysis training program (report CPT 90989 for completed course or 90993 per training session if incomplete), has a well‑functioning vascular access, and—when applicable—justifies the need for staff‑assisted (skilled) home hemodialysis.

    • Include completed training documentation (CPT 90989) or session records (CPT 90993).
    • Document vascular access type and function and any reasons skilled care is required (inability of patient/caregiver to perform HHD).
    Documentation Required

    Document patient characteristics and training

    Document patient‑specific characteristics that influenced selection for HHD, including age, comorbidities, prior dialysis regimen, and demonstrated training capability, because many studies included younger or healthier participants and observational evidence is subject to selection bias.

    • Record patient's age, comorbid conditions, prior in‑center dialysis experience, and caregiver availability/ability.
    • Note any study limitations referenced when using literature to support the request.
    Documentation Required

    Reference member‑specific benefit documents

    When deciding coverage and preparing prior authorization documentation, reference the member‑specific benefit plan document and any applicable federal or state mandates; document which plan provisions or mandates were used in the decision.

    • Specify the member plan name and relevant clauses relied upon in the PA submission.
    • For Medicare Advantage members, note whether NCD/LCD exist or whether MAO rationale is being used.
    Denial Risk

    Denial triggers if medical necessity not met

    Claims or PA requests may be denied if the individual does not meet the medical necessity criteria for HHD—examples include being unstable on dialysis, requiring skilled interventions during treatments, lacking completed training or an available caregiver, having contraindicating comorbidities, or lacking a well‑functioning vascular access.

    • Denials likely when documentation fails to show stability, training completion (or plan for training), adequate access, or absence of unsafe comorbidities.
    • For staff‑assisted requests, justify why patient/caregiver cannot perform HHD and why leaving home is contraindicated.
    Denial Risk

    Selection and documentation risks for HHD requests

    Because observational studies may reflect selection of healthier or higher‑resource patients to HHD, failing to document clinical suitability and reasons for selecting HHD (versus patient preference alone) increases the risk of denial; include objective clinical measures and rationale to mitigate selection‑bias concerns.

    • Provide objective measures (clinical stability, lab trends, access function) and explain why HHD is clinically appropriate for this patient.
    • Avoid relying solely on cited cohort benefits without patient‑specific justification.
    Denial Risk

    Member‑specific benefit plan governs coverage

    Coverage determinations must follow the member‑specific benefit plan; if the member's plan terms conflict with this policy, the member‑specific benefit plan governs and failure to adhere to plan terms can lead to denial.

    • Always verify and document the applicable member benefit provisions used to make the coverage determination.
    • If uncertainty exists for Medicare Advantage members, document whether MAO rationale or NCD/LCD was applied.
    Evidence summarySystematic reviews and trials show low strength of evidence that more frequent HD may lower BP, reduce LV mass, and improve some QOL measures, but may increase vascular access complications.
    Setting notesSome studies of more frequent HD were in-center, while in the U.S. most frequent HD is delivered at home using systems not tested in all RCTs.
    Longer HD — definition and clinical considerations
    DefinitionLonger hemodialysis is defined as treatments lasting four or more hours per session.
    Clinical effectsLonger HD (with or without increased frequency) showed low-strength evidence for improved BP and shorter time to recovery, but inconsistent effects on mortality.
    Risk balanceLonger treatments may be associated with increased vascular access complications in some studies; benefits must be weighed against risks.
    Nocturnal HD (NHD)
    DefinitionNocturnal HD (NHD) refers to frequent overnight home hemodialysis, often performed six times weekly in trials.
    Key trial findingsThe FHN Nocturnal Trial randomized participants to six-times-weekly nocturnal home dialysis versus thrice-weekly HD and found improved phosphate and BP control but no significant effect on primary outcomes (death or LV mass) and a trend toward increased vascular access events.
    Post-trial considerationsAfter the 1-year trial, participants could modify prescriptions; extended follow-up raised concerns that require careful interpretation for routine use.
    Conventional in-center hemodialysis
    Typical scheduleConventional in-center hemodialysis is usually performed three times per week for 3 to 5 hours per session.
    PurposeProvides ultrafiltration and diffusion to remove excess fluid and small molecule waste, improving symptoms and quality of life for some patients.
    AlternativesIn-center short frequent HD may be offered as an alternative to conventional thrice-weekly HD after considering patient preferences, benefits, and risks.
    Single pool Kt/V — recommended targets
    Definition / targetSingle-pool Kt/V (spKt/V) recommended target is 1.4 per hemodialysis session for patients treated thrice weekly, with a minimum delivered spKt/V of 1.2.
    Dose adjustmentAdjust dialysis dose for patients with significant residual kidney function (Kru) and measure Kru periodically.
    Clinical rationalespKt/V targets guide adequacy of dialysis to reduce symptoms and metabolic derangements; targets are from NKF/KDOQI 2015 guidelines.
    Long-duration home hemodialysis (HHD)
    DefinitionLong-duration home hemodialysis typically refers to sessions of 6–8 hours, performed 3 to 6 nights per week.
    Patient selectionConsider long-duration HHD for patients who prefer this therapy for lifestyle reasons, per NKF/KDOQI guidance.
    Evidence cautionNKF/KDOQI noted inconclusive data regarding efficacy and potential increased risk; no firm recommendations were made for routine home long frequent HD, so patient preference and careful monitoring are important.